Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
Paclitaxel
Jazz Pharmaceuticals Ireland Limited
Ovarian Cancer
1 trial -
Palazestrant
Olema Pharmaceuticals
Metastatic Breast Cancer
1 trial -
Pantoprazole Sodium 40 mg delayed-release tablets
Teva Pharma GmbH
Healthy
2 trials -
Paracetamol 1000mg Tablets, Diphenhydramin-Hevert Injektionslösung, Diphenhydramine Hydrochloride Tablets 25 mg, LYNOZYFIC 200 mg concentrate for solution for infusion, LYNOZYFIC 5 mg concentrate for solution for infusion, Dexamethasone 3.3 mg/ml solution for injection/infusion, REGN17372
Lacuna Pharma Pty Ltd
Relapsed/Refractory Multiple Myeloma
1 trial -
Paroxetine HCl
Teva Pharma GmbH
Healthy
2 trials -
PegInterferon
Vertex Pharmaceuticals (Australia) Pty.
Chronic Hepatitis C
1 trial -
Pegfilgrastim
Biotech Pharmaceutical Co.,
Breast Cancer
1 trial -
Peginterferon lambda
Biotech Pharmaceutical Co.,
Hepatitis C
1 trial -
Pegylated Recombinant Candida Utilis Uricase for Injection
Sunshine Guojian Pharmaceutical (Shanghai) Co.,
Gout
1 trial -
Period 1: AT-527 550 mg
Atea Pharmaceuticals
Healthy Volunteer Study
1 trial -
Pharmaceutical-lipid aspirin (PL-ASA)
Protalix BioTherapeutics
Bioequivalence
1 trial -
Pharmacogenomics testing for clopidogrel responsiveness
BRIGHT MINDS BIOSCIENCES INC.
Stroke
1 trial -
Pharmacokinetic comparison of efanesoctocog alfa vs other EHL-rFVIII products in participants with severe haemophilia A
Swedish Orphan Biovitrum AB (publ)
Haemophilia A
1 trial -
Pharmacokinetic study of colistimethate sodium
Zaklady FarmaFarmaceutyczne Polpharma S.Aceutyczne Polpharma S.A.
serious infections caused by selected aerobic gram-negative pathogens in patients with limited treatment options
1 trial -
Pharmacokinetic study of minocycline in patients with nontuberculous mycobacterial disease
Disc Medicine
Nontuberculous mycobacterial disease
1 trial -
Pharmacokinetic, Safety, Tolerability, and Immunogenicity Comparison of CKD-704 (risankizumab biosimilar), with EU-approved Skyrizi®, and US licensed Skyrizi® in Healthy Adult Participants
Lacuna Pharma Pty Ltd
Active psoriatic arthritis, Moderately to severely active Crohn’s disease, Moderate-to-severe plaque psoriasis, Moderately to severely active ulcerative colitis
1 trial -
Pharmacokinetics, pharmacodynamics, safety, and tolerability of an acetonic milk thistle extract, standardized to silymarin, in subjects with MASLD
Topiloric/Uriadec
chronic liver disease
1 trial -
Pharmacy-based methadone administration and dispensing
BRIGHT MINDS BIOSCIENCES INC.
Opioid-use Disorder
1 trial -
Phase 1 Safety and Tolerability Study of ALN-F1202 in Healthy Adults.
Lacuna Pharma Pty Ltd
Healthy Volunteer
1 trial -
Phase 1 Safety and Tolerability Study of REGN9533 in Healthy Adults.
Lacuna Pharma Pty Ltd
Healthy Volunteers
1 trial -
Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors
Olema Pharmaceuticals
Advanced or Metastatic Solid Tumors
1 trial -
Phase 1 Study of Revumenib in Combination with Intensive Chemotherapy in Participants with AML Harboring Alterations in KMT2A/MLL, NPM1, or NUP98 Genes
Syndax Pharmaceuticals
Acute Myeloid Leukemias
1 trial -
Phase 1 dose-escalation trial of OMTX705, an anti-fibroblast activation protein antibody-drug conjugate, as single agent and in combination with anti-PD-1 or pazopanib in patients with advanced solid tumors
Lacuna Pharma Pty Ltd
Selected tumor indications that are known to express FAP (Fibroblast activation protein) either on tumor stroma CAFs (Cancer-associated fibroblasts) (carcinomas) or on tumor cells (leiomyosarcomas and other sarcomas).
1 trial -
Phase 1, Open-Label, single arm (Non-comparator) Study to Evaluate the Pharmacokinetics and Safety of a Single Dose of Oral Gepotidacin in Addition to Antibacterial Standard of Care in Pediatric Participants from 2 to less than 12 years of age with a Suspected or Confirmed Bacterial Infection or Receiving Prophylaxis with Antibiotics
GlaxoSmithKline
Urinary Tract Infections
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources